Skin Condition
Conditions
Brief summary
To assess the efficacy of Wasabi Leaf Extract on skin
Interventions
DIETARY_SUPPLEMENTPlacebo drink
consume 1 bottle per day
DIETARY_SUPPLEMENTWasabi Leaf Extract Drink
consume 1 bottle per day
Sponsors
TCI Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* 20 to 65-year-old males or females * People with dull skin, pigmentation spots or acne-prone, acne scars * Acne severity assessment- Investigator's Global Assessment Scale (IGA) ≥ 2
Exclusion criteria
* Received medical cosmetic treatment (including cosmetic skin care, laser, fruit acid peeling, injection or plastic surgery, etc.) currently or within one month before the trial * Outdoor workers (exposed to the sun more than 5 hours a day) * People who are breastfeeding, pregnant or planning to become pregnant during the test (self-report) * People with heart, liver, kidney, endocrine and other major organic diseases (self-reported) * People who have undergone major surgery (according to medical history) * People who take drugs for a long time * People with mental illness * Students who are currently taking courses taught by the principal investigator of this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change of Insulin-Like Growth Factor-1 of blood | Change from Baseline IGF-1 at 8 weeks | Venous blood was sampled to measure IGF-1 |
| The change of transepidermal water loss | Change from Baseline TEWL at 8 weeks | Tewameter® TM300 was utilized to measure transepidermal water loss (TEWL). Units: TEWL-values lower than 70 g/hm² |
| The change of L* (lightness) values | Change from Baseline L* value at 8 weeks | Spectrophotometer SCM-108 was utilized to measure skin L\* value. Units: arbitrary units |
| The change of a* (redness) values | Change from Baseline a* value at 8 weeks | Spectrophotometer SCM-108 was utilized to measure skin a\* value. Units: arbitrary units |
| The change of visible spots | Change from Baseline visible spots at 8 weeks | VISIA Complexion Analysis System was utilized to measure skin spots. Units: arbitrary units |
| The change of skin red area | Change from Baseline skin red area at 8 weeks | VISIA Complexion Analysis System was utilized to measure skin red area. Units: arbitrary units |
| The change of total antioxidant capacity of blood | Change from Baseline total antioxidant capacity at 8 weeks | Venous blood was sampled to measure total antioxidant capacity |
| The change of Interleukin-6 of blood | Change from Baseline IL-6 at 8 weeks | Venous blood was sampled to measure IL-6 |
| The change of Interleukin-8 of blood | Change from Baseline IL-8 at 8 weeks | Venous blood was sampled to measure IL-8 |
| The change of skin melanin index | Change from Baseline skin melanin index at 8 weeks | Mexameter® MX18 was utilized to measure skin melanin index. Units: arbitrary Mexameter® units (0-999) |
| The change of skin erythema index | Change from Baseline skin erythema index at 8 weeks | Mexameter® MX18 was utilized to measure skin erythema index. Units: arbitrary Mexameter® units (0-999) |
| The change of skin sebum content | Change from Baseline skin sebum content at 8 weeks | Sebumeter® SM815 was utilized to measure skin sebum content. Units: Sebumeter® units from 0-350 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change of UV spots | Change from Baseline UV spots at 8 weeks | VISIA Complexion Analysis System was utilized to measure UV spots. Units: arbitrary units |
| The change of brown spots | Change from Baseline brown spots at 8 weeks | VISIA Complexion Analysis System was utilized to measure brown spots. Units: arbitrary units |
| The change of Advanced glycation end products of blood | Change from Baseline AGEs at 8 weeks | Venous blood was sampled to measure AGEs |
| The change of liver function biomarkers (AST, ALT) of blood | Change from Baseline liver function biomarkers at 8 weeks | Venous blood was sampled to measure liver function biomarkers |
| The change of renal function biomarkers (creatinine, BUN) of blood | Change from Baseline renal function biomarkers at 8 weeks | Venous blood was sampled to measure renal function biomarkers |
| The change of fasting blood glugose level | Change from Baseline fasting blood glugose level at 8 weeks | Venous blood was sampled to measure fasting blood glugose level |
| The change of blood lipid profile | Change from Baseline blood lipid profile at 8 weeks | Venous blood was sampled to measure blood lipid profile (total cholesterol, HDL-C, LDL-C, triglyceride) |
| The change of skin hydration | Change from Baseline skin hydration at 8 weeks | Corneometer® CM825 was utilized to measure skin hydration. Units: arbitrary |
Countries
Taiwan
Outcome results
None listed